Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy.
Depression
Electroconvulsive therapy
Malignant hyperthermia
Neuroleptic malignant syndrome
Serotonin syndrome
Succinylcholine
Suxamethonium
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
02
02
2024
accepted:
14
05
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
4
6
2024
Statut:
epublish
Résumé
Malignant hyperthermia is a potentially lethal condition triggered by specific anesthetic drugs, especially a depolarizing muscle relaxant of succinylcholine (Suxamethonium). Despite the frequent use of succinylcholine with electroconvulsive therapy (ECT), there has been no reported case of potentially lethal malignant hyperthermia following ECT. In addition, the time interval between the administration of succinylcholine and the onset of malignant hyperthermia has not been outlined in the context of ECT. We present the case of a 79-year-old woman suffering from severe depression, who experienced severe malignant hyperthermia due to succinylcholine administration during an ECT session. She presented with a high fever of 40.2 °C, tachycardia of 140/min, hypertension with a blood pressure exceeding 200 mmHg, significant muscle rigidity, and impaired consciousness. These symptoms emerged two hours after ECT, which occurred in a psychiatric ward rather than an operating room, and reached their peak in less than 24 h. She was given 60 mg of dantrolene, which quickly reduced the muscular rigidity. Subsequently, she received two additional doses of 20 mg and 60 mg of dantrolene, which brought her fever down to 36.2 °C and completely eased her muscle rigidity within two days after ECT. This is the first reported case of potentially lethal malignant hyperthermia after ECT. In addition, it highlights the delayed onset of malignant hyperthermia following an ECT procedure, emphasizing the necessity for psychiatrists to recognize its onset even after the treatment. In the light of potentially lethal consequences of malignant hyperthermia, it is critically important for psychiatrists to closely monitor both intraoperative and postoperative patient's vital signs and characteristic physical presentations, promptly identify any symptomatic emergence, and treat it immediately with dantrolene.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant hyperthermia is a potentially lethal condition triggered by specific anesthetic drugs, especially a depolarizing muscle relaxant of succinylcholine (Suxamethonium). Despite the frequent use of succinylcholine with electroconvulsive therapy (ECT), there has been no reported case of potentially lethal malignant hyperthermia following ECT. In addition, the time interval between the administration of succinylcholine and the onset of malignant hyperthermia has not been outlined in the context of ECT.
CASE PRESENTATION
METHODS
We present the case of a 79-year-old woman suffering from severe depression, who experienced severe malignant hyperthermia due to succinylcholine administration during an ECT session. She presented with a high fever of 40.2 °C, tachycardia of 140/min, hypertension with a blood pressure exceeding 200 mmHg, significant muscle rigidity, and impaired consciousness. These symptoms emerged two hours after ECT, which occurred in a psychiatric ward rather than an operating room, and reached their peak in less than 24 h. She was given 60 mg of dantrolene, which quickly reduced the muscular rigidity. Subsequently, she received two additional doses of 20 mg and 60 mg of dantrolene, which brought her fever down to 36.2 °C and completely eased her muscle rigidity within two days after ECT.
CONCLUSIONS
CONCLUSIONS
This is the first reported case of potentially lethal malignant hyperthermia after ECT. In addition, it highlights the delayed onset of malignant hyperthermia following an ECT procedure, emphasizing the necessity for psychiatrists to recognize its onset even after the treatment. In the light of potentially lethal consequences of malignant hyperthermia, it is critically important for psychiatrists to closely monitor both intraoperative and postoperative patient's vital signs and characteristic physical presentations, promptly identify any symptomatic emergence, and treat it immediately with dantrolene.
Identifiants
pubmed: 38834964
doi: 10.1186/s12888-024-05846-5
pii: 10.1186/s12888-024-05846-5
doi:
Substances chimiques
Succinylcholine
J2R869A8YF
Neuromuscular Depolarizing Agents
0
Dantrolene
F64QU97QCR
Types de publication
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
411Informations de copyright
© 2024. The Author(s).
Références
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93. https://doi.org/10.1186/s13023-015-0310-1 .
doi: 10.1186/s13023-015-0310-1
pubmed: 26238698
pmcid: 4524368
Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007–2012: a report from the north American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesth Analg. 2014;119(6):1359–66. https://doi.org/10.1213/ANE.0000000000000421 .
doi: 10.1213/ANE.0000000000000421
pubmed: 25268394
Lazarus A, Rosenberg H. Malignant hyperthermia during ECT. Am J Psychiatry. 1991;148(4):541–2. https://doi.org/10.1176/ajp.148.4.541b .
doi: 10.1176/ajp.148.4.541b
pubmed: 2006702
Inada T, Iwamoto K, Takahashi N, Yamamoto N. Mastering the use of MADRS:clinical assessment of depression using the Japanese version of MADRS with SIGMA: revised 3rd edition. Tokyo: JIHO; 2013.
Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80(4):771–9. https://doi.org/10.1097/00000542-199404000-00008 .
doi: 10.1097/00000542-199404000-00008
pubmed: 8024130
Chemnitz G, Schmidt E, Koller PU, Busch EW. 1979. Kreatinkinase. Uberarbeitete Standardmethode: Referenzwerte und Klinik [Creatine kinase: reference values and clinical aspects of the revised standard method (author’s transl)]. Dtsch Med Wochenschr. 104(7), 257 – 60. German. https://doi.org/10.1055/s-0028-1103881 .
Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: preventing, recognizing, and treating it. Cleve Clin J Med. 2016;83(11):810–7. https://doi.org/10.3949/ccjm.83a.15129 .
doi: 10.3949/ccjm.83a.15129
pubmed: 27824534
Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13(3):395–406. https://doi.org/10.2174/1570159x13999150424113345 .
doi: 10.2174/1570159x13999150424113345
pubmed: 26411967
pmcid: 4812801
Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50(5):281–94. https://doi.org/10.2165/11539240-000000000-00000 .
doi: 10.2165/11539240-000000000-00000
pubmed: 21366359
Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Med (Baltim). 2000;79(4):201–9. https://doi.org/10.1097/00005792-200007000-00001 .
doi: 10.1097/00005792-200007000-00001
Boyer EW, Shannon M. 2005. The serotonin syndrome. N Engl J Med. 17;352(11), 1112-20. doi: 10.1056/NEJMra041867. Erratum in: N Engl J Med. 2007;356(23), 2437. Erratum in: N Engl J Med. 2009;361(17), 1714.
Jones D, Story DA. Serotonin syndrome and the anaesthetist. Anaesth Intensive Care. 2005;33(2):181–7. https://doi.org/10.1177/0310057X0503300205 .
doi: 10.1177/0310057X0503300205
pubmed: 15960399
Birmes P, Schmitt CD, Lauque L, D. Serotonin syndrome: a brief review. CMAJ. 2003;27(11):1439–42.
White DA, Robins AH. An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome. CNS Spectr. 2000;5(7):58–65. https://doi.org/10.1017/s1092852900013419 .
doi: 10.1017/s1092852900013419
pubmed: 18197157
Larach GM, Gronert AG, Allen CG, Brandom WB, Lehman BE. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2006;110(2):498–507. https://doi.org/10.1213/ANE.0b013e3181c6b9b2 .
doi: 10.1213/ANE.0b013e3181c6b9b2
Sheila R, Green ML, Charles H, Duminda W, Christine M, Natalia K. Malignant hyperthermia in Canada: characteristics of Index Anesthetics in 129 malignant Hyperthermia Susceptible Probands. Anesth Analgesia. 2014;118(2):381–7. https://doi.org/10.1213/ANE.0b013e3182937d8b .
doi: 10.1213/ANE.0b013e3182937d8b
Sold M, Tschöp M, Sörensen N. Symptome Der Akuten Einklemmung Nach Narkoseeinleitung Bei Hydrocephalus–in Wahrheit eine maligne hyperthermie [Symptoms of acute cerebral hernia following induction of anesthesia in hydrocephalus–malignant hyperthermia in reality]. Anaesthesist. 1986;35(10):634–8. German.
pubmed: 3789392
Ortiz JF, Wirth M, Eskander N, Cozar JC, Fatade O, Rathod B. The genetic foundations of Serotonin Syndrome, neuroleptic malignant syndrome, and malignant hyperthermia: is there a genetic Association between these disorders? Cureus. 2020;12(9):e10635. https://doi.org/10.7759/cureus.10635 .
doi: 10.7759/cureus.10635
pubmed: 33123448
pmcid: 7584300
Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. Handb Clin Neurol. 2018;157:663–75. https://doi.org/10.1016/B978-0-444-64074-1.00039-2 .
doi: 10.1016/B978-0-444-64074-1.00039-2
pubmed: 30459031
Wappler F, Fiege M, Schulte am, Esch J. Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth. 2001;87:794–8. https://doi.org/10.1093/bja/87.5.794 .
doi: 10.1093/bja/87.5.794
pubmed: 11878537
Litman RS, Flood CD, Kaplan RF, Kim YL, Tobin JR. Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry. Anesthesiology. 2008;109(5):825–9. https://doi.org/10.1097/ALN.0b013e31818958e5 .
doi: 10.1097/ALN.0b013e31818958e5
pubmed: 18946294
Johnson GC, Santos AB. More on ECT and malignant hyperthermia. Am J Psychiatry. 1983;140(2):266–7. https://doi.org/10.1176/ajp.140.2.266c .
doi: 10.1176/ajp.140.2.266c
pubmed: 6849456
Neal CR, Ferdinand CK, Ycas J, Miller E. Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med. 2009;122(1):73–8. https://doi.org/10.1016/j.amjmed.2008.08.033 .
doi: 10.1016/j.amjmed.2008.08.033
pubmed: 19114174
Garcia W. Elevated creatine phosphokinase levels Associated with large muscle Mass another Pitfall in evaluating clinical significance of total serum CPK activity. JAMA. 1974;228(11):1395–6. https://doi.org/10.1001/jama.1974.03230360025017 .
doi: 10.1001/jama.1974.03230360025017
pubmed: 4406615
Castro D, Patil SM, Zubair M, Keenaghan M. 2024. Arterial Blood Gas. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. (version of 2024 Jan 8).
Lee YS, Kim WY, Lee SH, Baek SM, Ok SJ, Kim JH, Park YC. A case of malignant hyperthermia during anesthesia induction with sevoflurane -A case report-. Korean J Anesthesiol. 2010;59(SupplSuppl):S6–8. https://doi.org/10.4097/kjae.2010.59.S.S6 .
doi: 10.4097/kjae.2010.59.S.S6
pubmed: 21286462
pmcid: 3030058
Minami S, Ikeda A, Yamada K, Kajihama A, Shimizu H, Nagafuchi H. Pediatric fulminant malignant hyperthermia with severe electroencephalographic abnormality and brain damage: a case report. J Med Case Rep. 2023;17:140. https://doi.org/10.1186/s13256-023-03887-0 .
doi: 10.1186/s13256-023-03887-0
pubmed: 37061729
pmcid: 10105921
Dao QA, Mohapatra S, Kuza C, Moon ST. Traumatic brain injury and RSI is rocuronium or succinylcholine preferred? Curr Opin Anaesthesiol. 2023;36(2):163–7. https://doi.org/10.1097/ACO.0000000000001225 .
doi: 10.1097/ACO.0000000000001225
pubmed: 36729846
Sumitani M, Uchida K, Yasunaga H, Horiguchi H, Kusakabe Y, Matsuda S, Yamada Y. Prevalence of malignant hyperthermia and relationship with anesthetics in Japan: data from the diagnosis procedure combination database. Anesthesiology. 2011;114(1):84–90. https://doi.org/10.1097/ALN.0b013e318200197d . Erratum in: Anesthesiology. 2011;114(5):1257.
doi: 10.1097/ALN.0b013e318200197d
pubmed: 21169796
Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg. 2014;118(2):388–96. https://doi.org/10.1213/ANE.0000000000000062 .
doi: 10.1213/ANE.0000000000000062
pubmed: 24445637